Idexx Laboratories (IDXX) Net Income towards Common Stockholders (2016 - 2026)
Idexx Laboratories has reported Net Income towards Common Stockholders over the past 17 years, most recently at $248.2 million for Q4 2025.
- For Q4 2025, Net Income towards Common Stockholders rose 14.82% year-over-year to $248.2 million; the TTM value through Dec 2025 reached $1.1 billion, up 19.33%, while the annual FY2025 figure was $1.1 billion, 19.33% up from the prior year.
- Net Income towards Common Stockholders for Q4 2025 was $248.2 million at Idexx Laboratories, down from $274.6 million in the prior quarter.
- Over five years, Net Income towards Common Stockholders peaked at $294.0 million in Q2 2025 and troughed at $132.0 million in Q2 2022.
- A 5-year average of $210.7 million and a median of $207.9 million in 2021 define the central range for Net Income towards Common Stockholders.
- Biggest five-year swings in Net Income towards Common Stockholders: skyrocketed 82.6% in 2021 and later crashed 34.61% in 2022.
- Year by year, Net Income towards Common Stockholders stood at $162.8 million in 2021, then grew by 5.8% to $172.2 million in 2022, then increased by 12.96% to $194.5 million in 2023, then grew by 11.12% to $216.1 million in 2024, then increased by 14.82% to $248.2 million in 2025.
- Business Quant data shows Net Income towards Common Stockholders for IDXX at $248.2 million in Q4 2025, $274.6 million in Q3 2025, and $294.0 million in Q2 2025.